ZINZINO AB (PUBL): THE BOARD DECIDES TO ISSUE 200 000 STOCK OPTIONS

The Board of Directors Zinzino AB (publ) has decided to issue 200,000 stock options with the mandate of the AGM of the Company in 2018-05-15. The right to subscribe for new stock options shall, with exception of shareholders’ preferential rights, only be added to Dr. Paul Clayton, Member of the Zinzino’s Scientific Advisory Board.

The reason for the deviation from shareholders’ preferential rights is to create incentives for an important external partner that greatly contributes to the company’s positive development. Subscription of the stock options shall be subscribed by subscription on subscription list no later than 31 October 2018. The Board shall have the right to extend the subscription period. By acquisition of the stock options a premium based on the market value, which shall be determined by applying the Black & Scholes option valuation model, needs to be paid.

Each stock options shall entitle the holder to subscribe for a (1) new B share in the company at a subscription price of SEK 12, as from the registration of the stock options by Bolagsverket in Sweden until 31 October 2023. If all subscription options are exercised for subscription of shares, the company’s registered share capital will increase by SEK 20,000.


For more information: 

Fredrik Nielsen, CFO Zinzino, Mobile: +46 (0) 707 900 174
www.zinzino.com  


Pictures for publication free of charge: 

Marcus Tollbom, Mobile: +46 (0) 70 190 03 12  


Certified Adviser:
Erik Penser Bank Aktiebolag 
  

Zinzino AB (publ.) is a direct sales company that operates throughout Europe and North America. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 33 markets across Europe and North America. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, and in Florida, USA. Zinzino is a public company and its shares are listed on Nasdaq First North. In 2016, Zinzino was recognized with the award ‘’Superföretag 2015’’ by Veckans Affärer and the ‘’Gazelle’’ award by Dagens Industri.

Tags:

About Us

Zinzino AB (publ.) is a direct sales company which operates through the EU, North America and Australia. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns Norwegian BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has over 120 employees. The company has its registered office in Gothenburg, and offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public limited company and its shares are listed on Nasdaq First North.

Subscribe

Documents & Links